Asset
VELEDIMEX
Alaunos Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01397708 | phase1_2 | completed | 2011-08-01 | 2014-09-01 | Alaunos Therapeutics | Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma |
| NCT00815607 | phase1 | completed | 2009-04-01 | 2013-01-01 | Alaunos Therapeutics | Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma |
FDA applications (0)
This company has no applications containing this asset.